+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 19 Actively Recruiting clinical trials

D

Actively Recruiting

Researchers are studying the daily use of Rifapentine combined with Isoniazid to prevent tuberculosis in children under 13 years old, including those with and without HIV. This Phase III trial aims to find the appropriate dose of this combination taken once daily for 28 days. The study will include up to 144 children divided into two groups based on HIV status and will take place at multiple locations. Participants will receive the study drugs by oral dispersible tablets, grouped by weight into five categories. Children with HIV will also be assessed for their use of Dolutegravir as part of their antiretroviral therapy. The treatment period lasts 28 days, followed by a 24-week follow-up to monitor safety, tolerability, and drug levels in the blood. Both groups will be closely observed to assess how the drugs are processed in their bodies and any adverse effects. During the study, participants will have blood tests to measure drug concentrations and monitor liver, kidney, and blood cell function. Parent or guardian reports on treatment acceptability and adherence will be collected. Researchers will track adverse events throughout the treatment and follow-up periods. The total participation duration includes the initial 28-day dosing phase and subsequent 24 weeks of monitoring to ensure safety and effectiveness of the regimen.

Age: 0 - 13YearsAll GendersPhase 1Phase 2
11 locations
E

Actively Recruiting

Researchers are evaluating propranolol as a treatment for Kaposi Sarcoma in both children and adults. This open-label, single-arm trial aims to assess the safety and effectiveness of propranolol for this condition. The study is sponsored by the AIDS Malignancy Consortium and focuses on participants with biopsy-confirmed, measurable Kaposi Sarcoma who do not require immediate chemotherapy. Participants will take propranolol twice daily for an initial 12-week period, with dosing based on age children 12 years or younger receive 3 mgkgday divided twice daily, while those older than 12 years take 120 mg twice daily. After 12 weeks, responses will be evaluated participants with a complete response continue treatment for an additional 6 weeks, and those with a partial response continue for 12 more weeks. Throughout the study, participants will be closely monitored for treatment responses and safety. Researchers will assess outcomes such as objective response rates, dose-limiting toxicities, and treatment-emergent adverse events at one year. The study includes evaluations of time to recurrence and progression for both children and adults. Total participation may last up to 24 weeks of treatment with follow-up assessments.

All AgesAll GendersPhase 2
6 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating a laboratory-made antibody called ePGT121v1-LS that targets a specific part of the HIV virus. This trial involves generally healthy adults without HIV-1 and aims to assess the safety, side effects, proper dosing, how the body processes the drug, and how well it neutralizes HIV in the blood. The study also explores combinations of ePGT121v1-LS with two other antibodies, VRC07-523LS and PGDM1400LS, to see if they interact when used together. The trial is divided into two parts. Part A includes six groups where participants receive ePGT121v1-LS by intravenous IV infusion at varying doses, alone or combined with the other two antibodies, with treatments given at Week 0 and Week 24 over a total of 48 weeks. Part B has two groups where participants receive subcutaneous SC injections of ePGT121v1-LS alone or combined with the other antibodies at two visits spaced 12 weeks apart, with a total duration of 24 weeks. Participants will have scheduled clinic visits throughout the study periods to monitor safety and side effects, including local and systemic reactions and laboratory tests. Researchers will measure antibody levels in the blood, study how the antibodies behave over time, and evaluate their ability to neutralize HIV. The study also includes HIV testing, counseling, and assessment of participants risk behaviors, lasting up to 48 weeks depending on the group.

Age: 18Years - 55YearsAll GendersPhase 1
11 locations
O

Actively Recruiting

This research aims to provide continued access to study drugs for children and adolescents living with HIV-1 who have completed participation in certain prior clinical studies involving Gilead HIV treatments. The main goals are to allow these participants to keep receiving the study drug they were taking or switch to a specific combination drug called bictegraviremtricitabinetenofovir BFTAF, and to monitor the safety of these treatments. Participants will continue taking the study drugs they used in their parent studies, which may include various combinations of antiretroviral medications such as emtricitabinetenofovir alafenamide FTAF with a third agent, elvitegravircobicistatemtricitabinetenofovir alafenamide ECFTAF, or other combinations involving cobicistat and protease inhibitors. Dosages are adjusted based on the participants weight. Some participants may switch to BFTAF at a dose appropriate for their weight. During the study, participants will be monitored for adverse events and treatment safety over time. Researchers will measure how many eligible participants receive access to the study drugs and track any treatment-emergent side effects. The study may last up to several years, with ongoing assessments to ensure participant well-being and to collect safety data.

Age: 1Month +All GendersPhase 4
15 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are conducting a Phase 1 trial to study the GRAdHIVNE1 vaccine, which uses a gorilla adenovirus vector to target HIV. The study aims to evaluate the vaccines safety, tolerability, and ability to stimulate immune responses in healthy adults both living with and without HIV. This trial builds on earlier vaccine research and preclinical studies that highlighted the importance of broad T-cell responses for controlling HIVs diversity and immune evasion. Participants living without HIV will be randomly assigned to receive either one or two doses of the GRAdHIVNE1 vaccine at two possible dose levels or a placebo. Those living with HIV will receive either two doses of the vaccine or placebo. The vaccine doses studied are 5x1010 or 2x1011 units. The study uses a double-blind design to compare vaccine effects with placebo. Throughout the study, participants will be closely monitored for safety and side effects over several timeframes including 7 days, 28 days, and up to 19 months. Immune responses will be measured repeatedly for up to 19 months to assess the vaccines impact. Participants will complete follow-up visits to evaluate adverse events, immune function, and overall health status during the trial period.

Age: 18Years - 50YearsAll GendersPhase 1
3 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, and immune responses of two experimental mRNA HIV vaccines in adults living with HIV who are generally healthy. This phase 1 trial aims to assess whether these vaccines can initiate or enhance antibody responses against HIV and how a carefully controlled break in antiretroviral therapy impacts these immune responses. About 42 participants will join the study at multiple sites. Participants will receive different vaccine schedules depending on their group one group will get DV700P-RNA at weeks 0 and 8, then DV701B1.1-RNA at week 16 the other group will get DV700P-RNA at week 0 and DV701B1.1-RNA at week 8. Both vaccines are given as intramuscular injections. The study includes a planned interruption of antiretroviral therapy to closely monitor immune responses during this time. During the study, participants will have regular assessments including monitoring for local and systemic reactions within 14 days after each vaccination, as well as tracking any adverse events throughout the study period of up to 88 weeks. Researchers will measure antibody responses and changes in HIV virus sequences at baseline, after vaccination, and following therapy restart. Blood tests, immune cell analysis, and safety labs will be conducted to evaluate vaccine effects and participant health over time.

Age: 18Years - 60YearsAll GendersPhase 1
16 locations
T

Actively Recruiting

Researchers are evaluating a multi-level intervention called TENDAI4PrEP designed to improve the uptake and persistence of oral pre-exposure prophylaxis PrEP among pregnant persons in Zimbabwe. This intervention adapts the TENDAI program, which helps reduce depression and increase HIV treatment adherence, to address barriers at the individual, community, and provider levels that affect PrEP use during pregnancy and postpartum. Zimbabwe faces a high HIV prevalence, especially among cisgender women of reproductive age, making prevention during pregnancy crucial. The study compares the TENDAI4PrEP problem-solving intervention, involving 4-5 sessions with a partner dyadic session and an optional postpartum booster, to enhanced treatment as usual ETAU. The intervention includes PrEP education, psychoeducation, and culturally adapted problem-solving therapy, while ETAU participants receive standard antenatal care with monthly visits, informational pamphlets about PrEP, and psychological referrals. Providers also receive group training to improve PrEP knowledge and address stigma. The study includes individual interviews, a proof-of-concept trial, and a pilot randomized controlled trial. Participants will be assessed for feasibility and acceptability of the intervention and provider training within 5 months post-baseline. They will complete self-reported adherence and psychological distress evaluations at 2 months, and PrEP persistence will be measured via urine at 3 months. Additional assessments will explore provider knowledge and stigma changes and implementation perceptions. The study aims to improve HIV prevention among pregnant persons through enhanced PrEP adherence support over the course of the trial, which runs until March 2027.

Age: 15Years - 55YearsAll GendersPhase Not Applicable
1 location
I

Actively Recruiting

Researchers are conducting an international observational study to better understand acute infections in adults who are hospitalized. This study focuses on patients with suspected or confirmed acute infectious diseases, including respiratory infections and emerging infectious diseases. The goal is to gather data and biospecimens that will help characterize these infections, identify risk factors, and inform future clinical trial designs. Participants in this study do not receive any experimental treatments as it is purely observational. The study collects detailed clinical data and biological samples from adults admitted to hospitals with acute infections. This includes patients with symptoms starting within the last 30 days. Data from multiple global sites will aid in comprehensively understanding the clinical course and management of these infections. During the study, participants health status will be monitored through various clinical assessments over a 28-day period. Researchers will measure outcomes such as mortality, recovery time, clinical improvement, organ support days, and organ failure scores. The study involves informed consent and follows participants during hospitalization and recovery to gather important information about acute infectious diseases and their progression.

Age: 18Years +All Genders
56 locations
S

Actively Recruiting

Healthy Volunteer

Malnutrition among women of reproductive age is a significant health issue in Sub-Saharan Africa, including Zimbabwe, affecting both mothers and their infants. This research investigates how maternal malnutrition and poor water, sanitation, and hygiene WASH conditions influence infant growth, intestinal microbiota development, immune system maturation, and the risk of intestinal inflammation and malnutrition. The study also considers maternal stress and mental health as factors potentially impacting infant care and health outcomes. The study follows pregnant women from at least 20 weeks gestation, divided into groups based on nutritional status and WASH living conditions. Four groups include malnourished and well-nourished women living in improved or poor WASH environments. Researchers will observe maternal and infant microbiota, breast milk composition, infant gut function, and immune responses from pregnancy through the infants first three years. The study includes detailed bio-sample collection and analysis at multiple time points to understand the role of environmental and biological factors in infant malnutrition. Participants will undergo regular assessments including maternal and infant stool, blood, and breast milk samples, alongside questionnaires on maternal stress and empowerment. Infant growth and health will be monitored through measures like mid-upper arm circumference, weight, height, and diarrhea episodes. The study aims to track infant intestinal inflammation, permeability, and immune cell populations, with follow-up visits continuing until the child reaches three years old. This comprehensive approach seeks to clarify how maternal and environmental factors contribute to infant malnutrition and development.

Age: 18Years +FEMALE
1 location
E

Actively Recruiting

Cervical cancer affects women in low- and middle-income countries, especially women living with HIV WLWH who face a higher risk. This research evaluates whether using two thermal ablation TA probes instead of one improves treatment for cervical precancerous lesions in WLWH. The study aims to support better cervical cancer prevention and contribute to the World Health Organizations goals for eliminating cervical cancer by 2030. Participants will first be screened using HPV testing or visual assessment. Those with positive results undergo exams including biopsies and imaging to assess eligibility. Eligible women with a type 1 transformation zone will receive TA treatment with either one or two probes, randomly assigned. Follow-up occurs at 6 months with HPV tests, biopsies, and visual exams. Women not eligible for TA will be referred for local care. During the study, participants will undergo clinical exams, digital imaging, and brush biopsies at enrollment and at 6 months. Researchers will measure the proportion of participants with persistent HPV at 6 months to assess treatment outcomes. The study monitors safety, acceptability, and feasibility of the two-probe method over the course of the trial, ending in May 2028.

Age: 25Years - 49YearsFEMALEPhase Not Applicable
1 location

1-10 of 19

1